Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 5, Mai 2008
Page(s) 525 - 528
Section M/S revues
DOI https://doi.org/10.1051/medsci/2008245525
Publié en ligne 15 mai 2008
  1. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155 : 1151–64.
  2. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299 : 1057–61.
  3. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4 : 330–6.
  4. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198 : 1875–86.
  5. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19 : 345–54.
  6. Ueno H, Klechevsky E, Morita R, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219 : 118–42.
  7. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5 : 296–306.
  8. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315 : 107–11.
  9. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008; 19 : 3–19.
  10. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147 : 258–67.
  11. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 1957; 147 : 268–73.
  12. Ferbas JJ, Toso JF, Logar AJ, et al. CD4+ blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection. J Immunol 1994; 152 : 4649–62.
  13. Sapoznikov A, Fischer JA, Zaft T, et al. Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J Exp Med 2007; 204 : 1923–33.
  14. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12 : 214–9.
  15. Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12 : 207–13.
  16. Bonmort M, Dalod M, Mignot G, et al. Killer dendritic cells: IKDC and the others. Curr Opin Immunol 2008 (sous presse).
  17. Blasius AL, Barchet W, Cella M, Colonna M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J Exp Med 2007; 204 : 2561–8.
  18. Caminschi I, Ahmet F, Heger K, et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med 2007; 204 : 2579–90.
  19. Vosshenrich CA, Lesjean-Pottier S, Hasan M, et al. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 2007; 204 : 2569–78.
  20. Spits H, Lanier LL. Natural killer or dendritic: what’s in a name ? Immunity 2007; 26 : 11–6.
  21. Ullrich E, Bonmort M, Mignot G, et al. Trans-presentation of interleukin-15 dictates IKDC effector functions. 2008 (sous presse).
  22. Welner RS, Pelayo R, Garrett KP, et al. Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors. Blood 2007; 109 : 4825–31.
  23. Mignot G, Ullrich E, Bonmort M, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008 (sous presse).
  24. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006; 176 : 1517–24.
  25. Ullrich E. Boston : Federation of Clinical Immunology Societies (FOCIS), 2008.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.